Author:
Meuth S. G.,Ruck T.,Aktas O.,Hartung H.-P.
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Clinical Neurology,Neurology,General Medicine
Reference40 articles.
1. Baker D, Herrod SS, Alvarez-Gonzalez C et al (2017) Both cladribine and alemtuzumab may affect MS via B‑cell depletion. Neurol Neuroimmunol Neuroinflamm 4:e360
2. Beutler E (1992) Cladribine (2-chlorodeoxyadenosine). Lancet 340:952–956
3. ClinicalTrials.gov (2017) Prospective observational long-term safety registry of multiple sclerosis patients who have participated in Cladribine clinical trials (PREMIERE)
www.clinicaltrials.gov
; NCT01013350
4. Cohen A, Hirschhorn R, Horowitz SD et al (1978) Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci U S A 75:472–476
5. Cook S, Leist T, Comi G et al (2016) Cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis of safety from the multiple sclerosis clinical development program. Congress of the European Committee for Treatment and Research in Multiple Sclerosis, London (Poster P644)
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献